- Analysts focus on three programs in big year for Bristol MyersWall Street’s expectations for Bristol Myers Squibb’s upcoming slate of data readouts are reaching a fever pitch. Analysts lobbed questions regarding at least half a dozen trial results expected…Endpoints · 2mo ago↗ source
- XTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue risePlus, news about PCI Pharma: 🏭 XTL Bio steps into psychedelics: XTL Biopharmaceuticals is acquiring 100% of the outstanding shares of psychedelic-focused biotech Psyga Bio. XTL will gain Psyga’s…Endpoints · 2mo ago↗ source
- What we heard at a health tech conference in BostonI just came back from the Digital Healthcare Innovation Summit in Boston earlier this week, where I got a good look into what investors are thinking about. A few impressions: Investors see a ...